Usability, Safety and Efficacy of AspivixTM (Comparative Study)

IUD Insertion Clinical Trial

Official title:

Usability, Safety and Efficacy of AspivixTM, an Atraumatic Innovative Uterine Cervical Traction Device: a Pilot Phase Followed by a Comparative Study (Comparative)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04441281
• Other study ID #: Aspivix_IUD2019_Comparative
• Status: Completed
• Phase: N/A
• Start date: April 30, 2021
• Est. completion date: February 15, 2022

Study information

• Verified date: February 2022
• Source: Aspivix SA
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Limited mobility of the uterine cervix and alignment with the vaginal canal is often required during insertion of an intrauterine contraceptive device (IUD). Currently, the available instruments are traumatic tenacula, which could cause pain and bleeding and therefore represent an obstacle for certain patients to pursue their medical follow-up. AspivixTM is a new device, which enables atraumatic traction of the cervix while respecting its specific semi-circular anatomic shape through a system powered by a vacuum chamber. The aim of our comparative study is to assess the patient's pain and bleeding using the AspivixTM device in comparison with a commonly used single-tooth tenaculum (Pozzi forceps). Additionally, the comparative study aims to assess and compare the safety of the AspivixTM device with the single-tooth tenaculum (Pozzi forceps). Note: Study is made of 2 phases (pilot phase followed by a comparative phase). Details regarding pilot study is registered separately.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 120
• Est. completion date: February 15, 2022
• Est. primary completion date: February 14, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Participants older than 18 years
• Participants presenting at the outpatient clinic IUD insertion of Mirena (BAYER), Kyleena (BAYER), Jaydess (BAYER), NOVAT 380 (BAYER), NT Cu380 mini (MONALISA), NT Cu380 (MONALISA), CuT 380A (MONALISA) or CuT 380A QL (MONALISA).
• Participants able to provide informed consent as documented by signature with at least 24 hours of reflection time
• Good understanding of written and oral speaking used at the centre where the study will be carried out.

Exclusion Criteria:

• Participants who are contraindicated for the insertion of the IUD Mirena (BAYER), Kyleena (BAYER), Jaydess (BAYER), NOVAT 380 (BAYER), NT Cu380 mini (MONALISA), NT Cu380 (MONALISA), CuT 380A (MONALISA) or CuT 380A QL (MONALISA).
• Participants under use of excessive alcohol, narcotics or benzodiazepines prior to procedure
• Participants who do not wish to be informed of a chance discovery
• Participant receiving anaesthetics prior to IUD insertion procedure
• Participants on anticoagulant medication
• Participants under use of an analgesic (< 12 hours)
• Previous cervical operation
• Severe vaginal bleeding of unknown origin
• Participant previously enrolled in this study
• Cervix diameter smaller than 26 mm
• Nabothian cyst
• Cervical myomas
• Cervical condylomas
• Squamous intraepithelial lesion (Cervical dysplasia)
• Cervical endometriosis
• Cervical tears
• A well exposed cervix and / or well aligned vaginal and cervical canals where no traction is required for IUD insertion
• Other cervical abnormalities (cervical polyp, cervical lesion, or irregularity) which may contraindicate or complicate IUD insertion
• Large ectopy, for which it is not possible to find a suitable location near the ectopy where native tissue is present
• Large scar tissue, for which it is not possible to find a suitable location near the scar where native tissue is present

Related Conditions & MeSH terms

• IUD Insertion

Intervention

Procedure:
• Traction of the cervix for IUD insertion
Limited mobility of the uterine cervix and alignment with the vaginal canal is often required during insertion of an intrauterine contraceptive device (IUD).

Locations

Country	Name	City	State
Switzerland	HUG - Department Women, Child & Adolescent	Geneva	Vaud
Switzerland	Department Women, Mother & Child, University Hospital	Lausanne	Vaud

Sponsors (1)

Lead Sponsor	Collaborator
Aspivix SA

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Patient-reported pain: Visual Analogic Scale	Patient-reported pain scores (VAS) at specific time points during IUD insertion procedure Minimal and maximal values range from 0 to 100, the higher being the better outcome.	Before the procedure
Primary	Patient-reported pain: Visual Analogic Scale	Patient-reported pain scores (VAS) at specific time points during IUD insertion procedure Minimal and maximal values range from 0 to 100, the higher being the better outcome.	During speculum insertion
Primary	Patient-reported pain: Visual Analogic Scale	Patient-reported pain scores (VAS) at specific time points during IUD insertion procedure Minimal and maximal values range from 0 to 100, the higher being the better outcome.	During AspivixTM / standard tenaculum application
Primary	Patient-reported pain: Visual Analogic Scale	Patient-reported pain scores (VAS) at specific time points during IUD insertion procedure Minimal and maximal values range from 0 to 100, the higher being the better outcome.	During application of cervical traction
Primary	Patient-reported pain: Visual Analogic Scale	Patient-reported pain scores (VAS) at specific time points during IUD insertion procedure Minimal and maximal values range from 0 to 100, the higher being the better outcome.	During IUD insertion
Primary	Patient-reported pain: Visual Analogic Scale	Patient-reported pain scores (VAS) at specific time points during IUD insertion procedure Minimal and maximal values range from 0 to 100, the higher being the better outcome.	During AspivixTM / standard tenaculum release
Primary	Patient-reported pain: Visual Analogic Scale	Patient-reported pain scores (VAS) at specific time points during IUD insertion procedure Minimal and maximal values range from 0 to 100, the higher being the better outcome.	5 minutes after the end of the procedure
Secondary	The number of placement attempts before traction can be applied	number of placement attempts before traction can be applied The number of placement attempts before traction of the cervix can be applied will be recorded	During the procedure to insert the IUD which should last less than 5 minutes.
Secondary	The number of spontaneous releases	The number of spontaneous releases during traction of the cervix will be recorded	During the procedure to insert the IUD which should last less than 5 minutes.
Secondary	Assessment of the efficacy of the investigational device and its comparator by the practitioner	5 point Likert 'Efficacy Questionnaire' will be used. Minimal to maximal values range from 1 to 5, 1 meaning "disagree" and 5 "agree".	During the procedure to insert the IUD which should last less than 5 minutes.
Secondary	Assessment of bleeding	To assess bleeding, every buffer will be weighted, and the blank weight subtracted. Weight in mg will be reported in the case report form.	During the procedure to insert the IUD which should last less than 5 minutes.
Secondary	Assessment of adverse events	Safety of the procedure will be assessed by documenting adverse events (description of the adverse events, number of participants)	During the procedure to insert the IUD which should last less than 5 minutes.
Secondary	Assessment of device deficiencies	Safety of the procedure will be assessed by documenting device deficiencies (description)	During the procedure to insert the IUD which should last less than 5 minutes.
Secondary	Identification of new risks	Safety of the procedure will be assessed by identifying and documenting any new risk.	During the procedure to insert the IUD which should last less than 5 minutes.